• CNM-Au8 is an oral suspension with demonstrated activity in restoring neuronal health and function by increasing energy production and utilization
• Treatment with CNM-Au8 investigated in clinical trials adjunctive to standard-of-care exhibits no known drug interactions, and aims to enhance function and survival
• Nearly 90,000 people are diagnosed with Parkinson’s disease every year with no approved drug to slow or halt disease progression currently available
• The Parkinson’s disease treatment market was valued at $4.61 billion in 2022 and is expected to reach $11.98 billion by 2030

In recognition of April as Parkinson’s Disease Awareness Month, IBN is highlighting Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including Parkinson’s disease (“PD”), amyotrophic lateral sclerosis (“ALS”), and multiple sclerosis (“MS”). Clene is developing its lead drug candidate CNM-Au8(R) for potential treatment of these neurodegenerative diseases. CNM-Au8 is an oral suspension designed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy-producing reactions that enable neuroprotection and remyelination. The result is an increase in neuronal and glial resilience to disease-relevant stressors.

In March 2021, Clene was awarded a grant from The Michael J Fox Foundation for Parkinson’s Research (“MJFF”) to accelerate the development of CNM-Au8 as a treatment for PD. The funding supports efficacy studies in a human cell culture model of PD that utilizes skin cells from individuals with…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN